Precision Biosciences
Open
$7.13
Prev. Close
$7.14
High
$7.17
Low
$7.13
Market Snapshot
$91.47M
-2.0
1.33
$68.7M
68
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 68 full-time employees. The company went IPO on 2019-03-28. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The firm's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The firm's iECURE-OTC program is developed in partnership with iECURE, Inc.
emptyResult
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 68 full-time employees. The company went IPO on 2019-03-28. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The firm's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The firm's iECURE-OTC program is developed in partnership with iECURE, Inc.
Recently from Cashu
Precision BioSciences Strengthens Leadership for Gene Editing Innovation and Growth
Precision BioSciences Enhances Leadership Team to Propel Gene Editing Advancements Precision BioSciences, Inc., a clinical-stage gene editing company, is poised for significant growth with the recent…
Precision BioSciences Showcases ARCUS Innovations at Upcoming Genetic Medicine Conferences
Precision BioSciences Advances Gene Editing Innovations Through Strategic Engagements Precision BioSciences, Inc., a leading clinical-stage gene editing company based in Durham, North Carolina, is set…
Precision BioSciences: Innovating Gene Editing with ARCUS® and Advancing Genetic Medicine
Precision BioSciences: Leading the Charge in Gene Editing Innovation Precision BioSciences, Inc., a clinical-stage gene editing company based in Durham, North Carolina, is at the forefront of advancin…
Precision BioSciences Advances PBGENE-HBV Gene Editing for Chronic Hepatitis B Treatment
Precision BioSciences Advances Gene Editing Therapy for Chronic Hepatitis B Precision BioSciences, Inc. is taking significant strides in the fight against chronic hepatitis B with the clinical develop…